The International Generic and Biosimilar medicines Association (IGBA) announced today the annual leadership change of its CEO Advisory Committee (AC). Lucas Sigman, CEO of Insud Pharma, has been appointed Chair and Allan Oberman, President and CEO of Apotex, Vice-Chair.
25 NOVEMBER 2024, BUSAN, SOUTH KOREA – This statement is delivered on behalf of IFPMA, GSCF, and IGBA, who collectively represent innovative, generic, and biosimilars pharmaceutical companies, as well as consumer healthcare manufacturers.
14 NOVEMBER 2024, GENEVA – We support a UN instrument to end plastics pollution through a harmonized, global approach that also prioritizes patient safety and safeguards access to medicinal and medical products.
- Global Biosimilars Week 2024 to Focus on Advancing Access to Biosimilars (November 2024)
- AMIP, the Moroccan Pharmaceutical Industry Association, joins IGBA (September 2024)
- IGBA identifies streamlined development through reduced comparative clinical studies and appropriate use of global comparator product as key to greater biosimilar access (July 2024)
- IGBA Statement at the Opening of the Sessions at the WIPO Assemblies (July 2024)
